GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition

$392,015
Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2021 · CA

Implications of the ATR Checkpoint Kinase in Radiation and Targeted Therapies

$391,954
Lee Zou · Massachusetts General Hospital · R01 · FY2020 · CA

Retroviral RLI immunomodulatory gene therapy for glioblastoma

$391,638
Manish Aghi · University Of California, San Francisco · R01 · FY2024 · NS

ST8Sia6 expression on tumors inhibits the immune response

$391,416
Virginia Smith Shapiro · Mayo Clinic Rochester · R01 · FY2023 · CA

ST8Sia6 expression on tumors inhibits the immune response

$391,416
Virginia Smith Shapiro · Mayo Clinic Rochester · R01 · FY2022 · CA

Regulation of Chromosome Segregation in Human Cells

$391,345
Prasad V Jallepalli · Sloan-Kettering Inst Can Research · R01 · FY2010 · GM

Targeting tumor innate immune signaling in pancreatic cancer

$391,277
Kian H Lim · Washington University · R01 · FY2025 · CA

Functional Analysis of p53 Polymorphic Variants

$391,227
Maureen E Murphy · Wistar Institute · R01 · FY2021 · CA

Functional Analysis of p53 Polymorphic Variants

$391,227
Maureen E Murphy · Wistar Institute · R01 · FY2023 · CA

Functional Analysis of p53 Polymorphic Variants

$391,227
Maureen E Murphy · Wistar Institute · R01 · FY2025 · CA

Dual-pronged nano-drug delivery using plant virus-like particles

$391,196
Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2022 · CA

Small Molecule Activators of Procaspases as Anti-Cancer Agents

$391,184
Paul Hergenrother · University Of Illinois At Urbana-Champaign · R01 · FY2019 · CA

Integration of neo-antigen vaccines and immune checkpoint therapy

$391,107
Elizabeth Marion Jaffee · Johns Hopkins University · P01 · FY2021 · CA

Integration of neo-antigen vaccines and immune checkpoint therapy

$391,107
Elizabeth Marion Jaffee · Johns Hopkins University · P01 · FY2025 · CA

Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition

$390,879
Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2020 · CA

Pro-tumor functions of neutrophils in squamous cell lung cancer

$390,763
Trudy Gale Oliver · Duke University · R01 · FY2024 · CA

Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma

$390,583
Gregory B. Lesinski · Emory University · R01 · FY2019 · CA

Administrative Supplement to 5DP1DA043893

$390,537
Peter S Kim · Stanford University · DP1 · FY2018 · DA

Mechanism and therapeutic potential of microglia regulation in glioblastoma

$390,425
Peiwen Chen · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · NS

DEREGULATION OF CELLULAR IKB KINASES BY HTLV1 TAX

$390,256
Vanderbilt University · R01 · FY2003 · CA

BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma

$390,134
Kapil N. Bhalla · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA

BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma

$390,134
Kapil N. Bhalla · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · CA

BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma

$390,134
Kapil N. Bhalla · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA

BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma

$390,134
Kapil N. Bhalla · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · CA

Project 2: Reversing STING-mediated immunosuppression in LKB1-mutant lung adenocarcinoma

$390,089
Haian Fu · Emory University · P01 · FY2023 · CA